Current Options for Second-Line Systemic Therapy in Metastatic Renal Cell Carcinoma.
angiogenesis
immunotherapy
renal cell carcinoma
second line
tyrosine kinase inhibitor
Journal
Journal of kidney cancer and VHL
ISSN: 2203-5826
Titre abrégé: J Kidney Cancer VHL
Pays: Australia
ID NLM: 101695919
Informations de publication
Date de publication:
2022
2022
Historique:
received:
13
06
2022
accepted:
26
08
2022
entrez:
31
10
2022
pubmed:
1
11
2022
medline:
1
11
2022
Statut:
epublish
Résumé
Standard systemic therapy of advanced renal cell carcinoma (RCC) involves targeting angiogenesis, mainly through tyrosine kinase inhibitors (TKI) against the vascular endothelial growth factor receptor (VEGFR) pathway and targeting the immune checkpoints, namely, programmed death-1 (PD-1) or its ligand (PD-L1), and cytotoxic T-lymphocyte-associated protein 4 (CTLA4). With current strategies of combining these two approaches in the front-line setting, less is known about optimal selection of therapy upon development of resistance in the second and later lines of treatment for progressive disease. This review discusses currently available therapeutic options in patients who have progressive RCC after prior treatment with double immune check-point inhibitors (ICIs) or ICI-TKI combinations.
Identifiants
pubmed: 36310639
doi: 10.15586/jkcvhl.v9i3.243
pii: JKCVHL-9-029
pmc: PMC9551369
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
29-40Informations de copyright
Copyright: Mitsogiannis IC, et al.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Clin Genitourin Cancer. 2013 Sep;11(3):270-5
pubmed: 23665131
J Clin Med. 2021 Nov 16;10(22):
pubmed: 34830621
Future Oncol. 2022 Mar;18(8):915-926
pubmed: 34911359
Int J Clin Oncol. 2020 Sep;25(9):1678-1686
pubmed: 32488547
Cell. 2017 Feb 9;168(4):707-723
pubmed: 28187290
Nat Med. 2021 May;27(5):802-805
pubmed: 33888901
Eur Urol. 2017 Aug;72(2):171-174
pubmed: 28359734
Clin Genitourin Cancer. 2019 Jun;17(3):e689-e703
pubmed: 31072748
BJU Int. 2022 May;129(5):610-620
pubmed: 34228889
Expert Rev Anticancer Ther. 2020 Jun;20(6):491-501
pubmed: 32479120
N Engl J Med. 2021 Mar 4;384(9):829-841
pubmed: 33657295
Int J Radiat Oncol Biol Phys. 2019 Oct 1;105(2):367-375
pubmed: 31377159
Br J Cancer. 2013 Apr 30;108(8):1571-8
pubmed: 23579211
Lancet Oncol. 2015 Nov;16(15):1473-1482
pubmed: 26482279
Cancer. 2008 Jul 1;113(1):78-83
pubmed: 18491376
Lancet Oncol. 2013 May;14(6):552-62
pubmed: 23598172
World J Urol. 2021 Nov;39(11):4183-4190
pubmed: 34043023
Oncologist. 2018 May;23(5):540-555
pubmed: 29487224
N Engl J Med. 2013 Aug 22;369(8):722-31
pubmed: 23964934
J Oncol. 2022 Feb 18;2022:3449660
pubmed: 35222642
N Engl J Med. 2021 Apr 8;384(14):1289-1300
pubmed: 33616314
Clin Genitourin Cancer. 2020 Feb;18(1):e37-e45
pubmed: 31727510
J Clin Oncol. 2010 Feb 20;28(6):1061-8
pubmed: 20100962
Orthopedics. 2021 Sep-Oct;44(5):e645-e652
pubmed: 34590940
J Natl Compr Canc Netw. 2022 Jan;20(1):71-90
pubmed: 34991070
Lancet Oncol. 2021 Dec;22(12):1732-1739
pubmed: 34717797
Eur Urol. 2021 Aug;80(2):162-170
pubmed: 33867192
Clin Exp Metastasis. 2021 Dec;38(6):527-537
pubmed: 34748125
Clin Genitourin Cancer. 2018 Oct;16(5):413-419.e1
pubmed: 30172552
J Clin Oncol. 2022 Jul 20;40(21):2333-2341
pubmed: 35298296
J Immunother Cancer. 2022 Mar;10(3):
pubmed: 35304405
BJU Int. 2021 Jun;127(6):703-711
pubmed: 33113260
Eur J Cancer. 2022 Aug;171:124-132
pubmed: 35717820
Clin Genitourin Cancer. 2017 Feb;15(1):122-128
pubmed: 27473522
J Clin Oncol. 2017 Feb 20;35(6):591-597
pubmed: 28199818
J Clin Oncol. 2020 Sep 20;38(27):3088-3094
pubmed: 32491962
Eur Urol. 2021 May;79(5):665-673
pubmed: 33678522
Br J Cancer. 2003 May 19;88(10):1516-21
pubmed: 12771915
Nat Commun. 2021 Jun 25;12(1):3969
pubmed: 34172722
Eur Urol. 2021 Dec;80(6):693-700
pubmed: 34399998
Eur J Cancer. 2016 Jul;62:28-35
pubmed: 27192659
CA Cancer J Clin. 2022 Jan;72(1):7-33
pubmed: 35020204
ESMO Open. 2022 Apr;7(2):100463
pubmed: 35405437
Eur Urol. 2022 Sep;82(3):283-292
pubmed: 35210132
Eur Urol. 2020 Dec;78(6):783-785
pubmed: 32938569
Ther Adv Urol. 2017 Jun 29;9(8):195-207
pubmed: 29662544
Eur Urol Oncol. 2022 Feb;5(1):125-133
pubmed: 34531172
Abdom Radiol (NY). 2018 Sep;43(9):2446-2454
pubmed: 29464274
Expert Rev Anticancer Ther. 2021 Sep;21(9):1029-1054
pubmed: 34445927
J Immunother Cancer. 2022 Feb;10(2):
pubmed: 35210307
Clin Genitourin Cancer. 2022 Jun;20(3):285-295
pubmed: 35305916
Cancer. 2020 Sep 15;126(18):4156-4167
pubmed: 32673417
Oncotarget. 2017 Aug 7;8(59):100708-100716
pubmed: 29246014
N Engl J Med. 2019 Mar 21;380(12):1116-1127
pubmed: 30779529
Semin Radiat Oncol. 2021 Jul;31(3):227-234
pubmed: 34090649
Cancers (Basel). 2020 Sep 18;12(9):
pubmed: 32961934
N Engl J Med. 2021 Nov 25;385(22):2036-2046
pubmed: 34818478
Int J Cancer. 2020 Mar 1;146(5):1307-1315
pubmed: 31498894
Lancet Oncol. 2020 Jan;21(1):95-104
pubmed: 31810797
J Clin Oncol. 2021 Mar 20;39(9):1029-1039
pubmed: 33529058
N Engl J Med. 2018 Apr 05;378(14):1277-1290
pubmed: 29562145
J Clin Oncol. 2014 Sep 1;32(25):2765-72
pubmed: 25049330
Eur Urol. 2022 Mar;81(3):274-282
pubmed: 34602312
Br J Cancer. 2017 Jun 27;117(1):1-7
pubmed: 28524159
Cancer Treat Res Commun. 2020;22:100161
pubmed: 31677494
Int J Urol. 2021 Jun;28(6):702-703
pubmed: 33719092
Eur Urol. 2017 Sep;72(3):368-376
pubmed: 28410865
Eur Urol. 2015 Nov;68(5):837-47
pubmed: 25952317
Eur Urol Oncol. 2021 Jun;4(3):502-505
pubmed: 31477526
Cancer Discov. 2017 Mar;7(3):264-276
pubmed: 28031159
Br J Cancer. 2018 Jan;118(1):9-16
pubmed: 29319049
Lancet Oncol. 2021 Jul;22(7):946-958
pubmed: 34143969
Drugs. 2021 Nov;81(16):1921-1927
pubmed: 34613603
Cancer Cell. 2021 May 10;39(5):649-661.e5
pubmed: 33711272
J Kidney Cancer VHL. 2020 Jun 02;7(1):7-11
pubmed: 32983840
Eur Urol Focus. 2021 May;7(3):598-607
pubmed: 32444303
Adv Radiat Oncol. 2021 May 26;6(5):100692
pubmed: 34646963
Eur Urol. 2022 Jul 14;:
pubmed: 35843777
Clin Genitourin Cancer. 2021 Dec;19(6):531-539
pubmed: 34112611
J Vasc Interv Radiol. 2012 Jun;23(6):770-7
pubmed: 22538119
Eur J Cancer. 2018 Jul;98:38-47
pubmed: 29864737
Lancet Oncol. 2019 Oct;20(10):1386-1394
pubmed: 31427205
J Clin Oncol. 2020 Nov 20;38(33):3863-3873
pubmed: 32910710
Lancet Oncol. 2016 Jul;17(7):917-927
pubmed: 27279544
Oncologist. 2017 Mar;22(3):311-317
pubmed: 28232599
PLoS One. 2017 Sep 8;12(9):e0184423
pubmed: 28886175
Ann Oncol. 2021 Dec;32(12):1511-1519
pubmed: 34597799
Lancet. 2011 Dec 3;378(9807):1931-9
pubmed: 22056247
Clin Genitourin Cancer. 2020 Dec;18(6):461-468.e3
pubmed: 32718906
Eur Urol Oncol. 2022 Apr;5(2):216-224
pubmed: 34986993
Target Oncol. 2019 Feb;14(1):33-38
pubmed: 30607698
Contemp Clin Trials Commun. 2021 Jan 06;21:100703
pubmed: 33490707
Clin Genitourin Cancer. 2021 Aug;19(4):354-361
pubmed: 33863648
Indian J Surg Oncol. 2018 Mar;9(1):105-109
pubmed: 29563747
J Clin Oncol. 2009 Jul 10;27(20):3312-8
pubmed: 19451442
Crit Rev Oncol Hematol. 2019 Dec;144:102816
pubmed: 31707222
Br J Cancer. 2014 Jun 10;110(12):2821-8
pubmed: 24823696
Ann Oncol. 2017 Jun 01;28(6):1339-1345
pubmed: 28327953
J Clin Oncol. 2014 May 10;32(14):1412-8
pubmed: 24687826
J Clin Oncol. 2010 Jul 1;28(19):3167-75
pubmed: 20516446
BMC Urol. 2016 Jul 04;16(1):34
pubmed: 27377922